Home LiteratureArticle Details
PMID: 26134505 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus.

European journal of pharmacology ·Vol. 764 ·2015-10-05 ·Pages 109-117

Ermund A, Meiss LN, Gustafsson JK, Hansson GC

Abstract

A non-functional Cystic Fibrosis Transmembrane conductance Regulator (CFTR) leads to the disease cystic fibrosis (CF). Although the CFTR is expressed in multiple organs, pulmonary disease is the major cause of illness and death in patients with CF. Stagnant mucus, causing airway obstruction, bacterial overgrowth, persistent inflammation and tissue destruction characterizes the disease, but how the defect in CFTR function is coupled to the mucus phenotype is still controversial. We have recently shown that bicarbonate ions passing through CFTR are necessary for proper unfolding of the MUC2 mucin, thus highlighting the importance of bicarbonate ion transport via the CFTR and the ability of these ions to raise the pH and chelate calcium bound to the mucin as the important steps in forming normal mucus. In order to find potential CF treatments and expand our knowledge about the usefulness of bicarbonate as an active ingredient in formulations to alleviate mucus plugging, we used an Ussing-type chamber and explants from the F508del-CFTR mutant mouse ileum to test the effect of calcium chelators on mucus attachment, either in isolation or in combination with osmolytes such as mannitol or hypertonic saline. We found that increasing the concentration of bicarbonate, both alone or in combination with increased osmolarity of the solution, detached the otherwise attached CF mucus.

Keywords
2 2ʹ 2ʺ 2‴-(Ethane-1 2-diyldinitrilo)tetraacetic acid (PubChem CID: 6049) Calcium chelator Carbachol (2-carbamoyloxyethyl(trimethyl)azanium Erdosteine (PubChem CID: 65632) Hyperosmolarity Mouse ileum Mucus attachment N-acetyl-l-cysteine (PubChem CID: 12035) Osmolyte Prostaglandin E(2) (PubChem CID: 5280360) Sodium bicarbonate (PubChem CID: 767) chloride) (PubChem CID: 5831) d-mannitol (PubChem CID:6251)
MeSH Terms
Animals Bicarbonates/pharmacology Calcium Chelating Agents/pharmacology Cystic Fibrosis/metabolism Cystic Fibrosis Transmembrane Conductance Regulator/genetics Female Ion Transport/drug effects Male Mice Mice, Inbred C57BL Mucus/drug effects,metabolism Mutation Osmolar Concentration
Chemicals
Bicarbonates Calcium Chelating Agents Cystic Fibrosis Transmembrane Conductance Regulator
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Ermund Anna
Department of Medical Biochemistry, University of Gothenburg, Medicinaregatan 9A, SE-413 90 Gothenburg, Sweden. Electronic address: Anna.Ermund@medkem.gu.se.
Meiss Lauren N
Department of Medical Biochemistry, University of Gothenburg, Medicinaregatan 9A, SE-413 90 Gothenburg, Sweden.
Gustafsson Jenny K
Department of Medical Biochemistry, University of Gothenburg, Medicinaregatan 9A, SE-413 90 Gothenburg, Sweden. Electronic address: Jenny.Gustafsson@medkem.gu.se.
Hansson Gunnar C
Department of Medical Biochemistry, University of Gothenburg, Medicinaregatan 9A, SE-413 90 Gothenburg, Sweden. Electronic address: Gunnar.Hansson@medkem.gu.se.
References (34)
34 references, click to expand
  1. Therapeutic options for hydrating airway mucus in cystic fibrosis.
    Pharmacology. 2015;95(3-4):117-32 PMID: 25823699
  2. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
    Cochrane Database Syst Rev. 2013 Jul 12;(7):CD007168 PMID: 23852992
  3. Mannitol dry powder for inhalation: in patients with cystic fibrosis.
    Drugs. 2012 Jul 9;72(10):1411-21 PMID: 22755516
  4. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion.
    J Clin Invest. 2009 Sep;119(9):2613-22 PMID: 19726884
  5. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications.
    Thorax. 2013 Dec;68(12):1157-62 PMID: 23704228
  6. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth.
    Aliment Pharmacol Ther. 2013 Jun;37(11):1103-11 PMID: 23574267
  7. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
    Am J Respir Crit Care Med. 2012 Mar 15;185(6):645-52 PMID: 22198974
  8. Cystic fibrosis.
    N Engl J Med. 2005 May 12;352(19):1992-2001 PMID: 15888700
  9. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?
    Respir Res. 2003;4:8 PMID: 14511398
  10. A mouse model for the cystic fibrosis delta F508 mutation.
    EMBO J. 1995 Sep 15;14(18):4403-11 PMID: 7556083
  11. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial.
    J Cyst Fibros. 2011 Jan;10(1):1-8 PMID: 20888307
  12. Erdosteine enhances mucociliary clearance in rats with and without airway inflammation.
    J Pharmacol Toxicol Methods. 1998 Oct;40(3):165-71 PMID: 10334633
  13. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
    Science. 1989 Sep 8;245(4922):1066-73 PMID: 2475911
  14. Antioxidant pharmacological therapies for COPD.
    Curr Opin Pharmacol. 2012 Jun;12(3):256-65 PMID: 22349417
  15. Hypertonic saline releases the attached small intestinal cystic fibrosis mucus.
    Clin Exp Pharmacol Physiol. 2015 Jan;42(1):69-75 PMID: 25311799
  16. Mucociliary clearance: pathophysiological aspects.
    Clin Physiol Funct Imaging. 2014 May;34(3):171-7 PMID: 24119105
  17. Calcium and pH-dependent packing and release of the gel-forming MUC2 mucin.
    Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5645-50 PMID: 22451922
  18. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.
    Chest. 2013 Aug;144(2):498-506 PMID: 23538783
  19. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
    Pulm Pharmacol Ther. 2010 Apr;23(2):135-44 PMID: 19854285
  20. Inhaled mannitol improves lung function in cystic fibrosis.
    Chest. 2008 Jun;133(6):1388-1396 PMID: 18339790
  21. Inhalation of dry-powder mannitol increases mucociliary clearance.
    Eur Respir J. 1997 Nov;10(11):2449-54 PMID: 9426077
  22. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype.
    J Exp Med. 2012 Jul 2;209(7):1263-72 PMID: 22711878
  23. Microbial-induced meprin β cleavage in MUC2 mucin and a functional CFTR channel are required to release anchored small intestinal mucus.
    Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12396-401 PMID: 25114233
  24. Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells.
    Respir Res. 2012 Oct 31;13:98 PMID: 23113953
  25. Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer's patches.
    Am J Physiol Gastrointest Liver Physiol. 2013 Sep 1;305(5):G341-7 PMID: 23832518
  26. Airway goblet cells: responsive and adaptable front-line defenders.
    Eur Respir J. 1994 Sep;7(9):1690-706 PMID: 7995400
  27. The neglected ion: HCO3-.
    Nat Med. 2001 Mar;7(3):292-3 PMID: 11231624
  28. An ex vivo method for studying mucus formation, properties, and thickness in human colonic biopsies and mouse small and large intestinal explants.
    Am J Physiol Gastrointest Liver Physiol. 2012 Feb 15;302(4):G430-8 PMID: 22159279
  29. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study.
    Eur Respir J. 1999 Sep;14(3):678-85 PMID: 10543292
  30. Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction.
    J Aerosol Med. 2002 Fall;15(3):331-41 PMID: 12396422
  31. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol.
    Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):758-65 PMID: 9309990
  32. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
    N Engl J Med. 2006 Jan 19;354(3):229-40 PMID: 16421364
  33. The effect of airflow on mucus secretion into the trachea of the cat.
    J Physiol. 1986 Nov;380:429-39 PMID: 3612569
  34. Mucoactive agents for airway mucus hypersecretory diseases.
    Respir Care. 2007 Sep;52(9):1176-93; discussion 1193-7 PMID: 17716385
Article Info
Journal
European journal of pharmacology
Abbr.
Eur J Pharmacol
ISSN
1879-0712
Published
2015-10-05
Epub
2015-00-30
Pages
109-117
Language
English
Region
Netherlands
NLM ID
1254354
PMCID
PMC4600443
Subset
IM
Grants
NIAID NIH HHS · U01 AI095473 · United States
NIAID NIH HHS · U01AI095473 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com